Patents Assigned to Pharmascience Inc.
  • Publication number: 20190076366
    Abstract: The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infections, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed.
    Type: Application
    Filed: April 3, 2018
    Publication date: March 14, 2019
    Applicant: Pharmascience, Inc.
    Inventors: Mathew Philip, Naresh Talwar
  • Publication number: 20180179210
    Abstract: The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 28, 2018
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
  • Publication number: 20180117158
    Abstract: A modified release orally administrable abuse-deterrent pharmaceutical composition comprising: a therapeutically effective amount of an active pharmaceutical ingredient and konjac glucomannan. The active pharmaceutical ingredient can be selected from a number of compounds but is generally aimed to be a compound which is subject to widespread abuse such as opioids.
    Type: Application
    Filed: December 27, 2017
    Publication date: May 3, 2018
    Applicant: Pharmascience Inc.
    Inventors: Krishna Hari Bhandari, Naresh Talwar
  • Patent number: 9822120
    Abstract: The present invention relates to a novel family of protein kinase inhibitors of Formula I: as well as to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 21, 2017
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Patent number: 9796716
    Abstract: The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: October 24, 2017
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose, James B. Jaquith
  • Patent number: 9795608
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: October 24, 2017
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose
  • Publication number: 20170158697
    Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated.
    Type: Application
    Filed: November 26, 2014
    Publication date: June 8, 2017
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Patent number: 9624239
    Abstract: The present invention relates to a novel family of inhibitors of protein kinases of Formula (1) wherein X is selected from CH2, O, S(0)n, or NR6; and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src, Btk and Lck protein kinase families.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: April 18, 2017
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
  • Publication number: 20170014340
    Abstract: Orally disintegrating medicaments comprising Nabilone allow for improved treatment of nausea arising from chemo therapy for cancer. The medicaments comprise appropriate excipients such that the medicament disintegrates in the mouth in 30 seconds or less, while exhibiting sufficient stability for storage. In a preferred embodiment, the medicament is in the form of a tablet formed from granules. The granules consist of an intra-granular fraction comprising nabilone, mannitol, and polyvinyl pyrrolidone and an extra-granular fraction comprising mannitol, calcium silicate, crospovidone, and magnesium stearate. Processes for manufacturfing such medicaments are also disclosed.
    Type: Application
    Filed: March 4, 2015
    Publication date: January 19, 2017
    Applicant: Pharmascience Inc.
    Inventors: Ousmane Diallo, Mathew Philip, Naresh Talwar
  • Publication number: 20160375027
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicant: PHARMASCIENCE, INC.
    Inventors: Alain LAURENT, Yannick ROSE
  • Publication number: 20160289236
    Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, their intermediates, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune, or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
    Type: Application
    Filed: November 19, 2014
    Publication date: October 6, 2016
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Publication number: 20160280711
    Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
    Type: Application
    Filed: November 20, 2014
    Publication date: September 29, 2016
    Applicant: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Patent number: 9447102
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: September 20, 2016
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose
  • Patent number: 9365614
    Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: June 14, 2016
    Assignee: Pharmascience Inc.
    Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
  • Publication number: 20160106680
    Abstract: The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compound selected from the group consisting of: polysaccharides, sugars, sugar derived alcohols, starches, starch derivatives, cellulose derivatives, Carrageenan, pectin, sodium alginate, gellan gum, xanthan gum, poloxamer, Carbopol®, PolyOx®, povidone, hydroxypropyl methylcellulose (HPMC), hypermellose, and combinations thereof; at least one disintegrant and optionally at least one surfactant, wherein said formulation exhibit properties related to deterring the abuse, via injection or nasal inhalation when being tampered and exposed to aqueous, alcoholic, acidic and basic media.
    Type: Application
    Filed: May 30, 2014
    Publication date: April 21, 2016
    Applicant: Pharmascience Inc.
    Inventors: Krishna Hari Bhandari, Naresh Talwar
  • Patent number: 9284350
    Abstract: A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: March 15, 2016
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Melanie Proulx, Yannick Rose, Irina Denissova, Kenza Dairi, Scott Jarvis, James B. Jaquith
  • Patent number: 9284318
    Abstract: The present invention relates to novel kinase inhibitors. Compounds of this class have been found to be effective inhibitors of protein kinases, including members of PDGFR and VEGFR families.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: March 15, 2016
    Assignee: Pharmascience, Inc.
    Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
  • Publication number: 20150250886
    Abstract: A modified release orally administrable abuse-deterrent pharmaceutical composition comprising: a therapeutically effective amount of an active pharmaceutical ingredient and konjac glucomannan. The active pharmaceutical ingredient can be selected from a number of compounds but is generally aimed to be a compound which is subject to widespread abuse such as opioids.
    Type: Application
    Filed: September 30, 2013
    Publication date: September 10, 2015
    Applicant: PHARMASCIENCE INC.
    Inventors: Krishna Hari Bhandari, Naresh Talwar
  • Publication number: 20150191473
    Abstract: The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.
    Type: Application
    Filed: May 28, 2013
    Publication date: July 9, 2015
    Applicant: Pharmascience, Inc.
    Inventors: Alain Laurent, Yannick Rose, James B. Jaquith
  • Publication number: 20140336134
    Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 13, 2014
    Applicant: Pharmascience Inc.
    Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent